A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook

Simply Wall St.02-28

Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, showing a move to full year profitability along with a weaker fourth quarter and a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614129518?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-28 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614129518","market":"hk","top_or_hot":-1,"title":"A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook","media":"Simply Wall St.","content":"<div>\n<p>Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, showing a move to full year profitability along with a weaker fourth quarter and a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/a-look-at-apellis-pharmaceuticals-apls-valuation-after-2025\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/a-look-at-apellis-pharmaceuticals-apls-valuation-after-2025><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, showing a move to full year profitability along with a weaker fourth quarter and a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/a-look-at-apellis-pharmaceuticals-apls-valuation-after-2025\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/a-look-at-apellis-pharmaceuticals-apls-valuation-after-2025","article_id":"2614129518","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/a-look-at-apellis-pharmaceuticals-apls-valuation-after-2025","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614129518","pubTimestamp":1772285245,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, showing a move to full year profitability along with a weaker fourth quarter and a more cautious outlook for Syfovre.\nSee our latest analysis for Apellis Pharmaceuticals.\nThe recent earnings release and more cautious commentary around Syfovre seem to have weighed on sentiment, with a 7 day share price return of 6.01% decline and a year to date share price return of 19.03%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","APLS":"Apellis Pharmaceuticals Inc.","BK4505":"高瓴资本持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC"},"translate_title":"2025年业绩后Apellis Pharmaceuticals(APLS)估值以及Syfovre增长前景疲软","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1.5},"content_text":"Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, showing a move to full year profitability along with a weaker fourth quarter and a more cautious outlook for Syfovre. See our latest analysis for Apellis Pharmaceuticals. The recent earnings release and more cautious commentary around Syfovre seem to have weighed on sentiment, with a 7 day share price return of 6.01% decline and a year to date share price return of 19.03% decline adding to a 1 year total shareholder return of 16.74% decline and a 3 year total shareholder return of 67.77% decline, suggesting momentum has been fading despite Apellis reaching full year profitability and progressing its pipeline. If this update has you reassessing biotech risk, it could be a good moment to widen your watchlist with our screener of 27 healthcare AI stocks as potential next ideas to research. With the shares down sharply over 1, 3 and 5 years, yet trading at a reported intrinsic discount of about 81% and a deep discount to analyst targets, you have to ask: is there genuine value here, or is the market already correctly bracing for slower growth? AdvertisementMost Popular Narrative: 38.3% Undervalued Apellis Pharmaceuticals' most followed valuation narrative pegs fair value at $33.95 per share versus the last close at $20.94. This frames a sizeable implied discount that rests heavily on how the kidney and eye franchises scale from here.  SYFOVRE maintains strong market leadership in geographic atrophy (GA), with over 60% market share and only ~10% market penetration to date, leaving significant runway for patient expansion as the global population ages and adoption among specialists and general ophthalmologists rises. Steady injection growth and broader awareness should drive increasing revenues over the long term.  Read the complete narrative. Curious how a single GA asset, a rare kidney launch and a premium future earnings multiple all combine into that fair value number? The narrative leans on aggressive earnings compounding, margin expansion and a rich valuation multiple that is closer to high growth stories than to typical biopharma peers. If you want to see exactly which revenue path and profitability step up have to line up to justify $33.95, the full narrative lays out the full blueprint. Beyond GA, the same narrative leans on expanded EMPAVELI use in rare kidney diseases and assumes Apellis can keep funding growth while still lifting profitability. It applies a discount rate of 7.31% to bring those modeled cash flows back to today and arrives at a fair value that sits well above both the last close and the current analyst price target cluster in the high $20s to mid $30s. Result: Fair Value of $33.95 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh the risk that SYFOVRE uptake underwhelms or key kidney trials disappoint, as this could undermine the current earnings and valuation story. Find out about the key risks to this Apellis Pharmaceuticals narrative. Another Angle On Valuation The 38.3% discount to fair value from the narrative model contrasts sharply with how the market is pricing Apellis today. On a P/E of 119.6x, compared with 23x for the US Biotechs industry, 26.5x for peers and a fair ratio of 33.6x, the stock screens as expensive. This raises a simple question: is the earnings outlook strong enough to close that gap? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:APLS P/E Ratio as at Feb 2026Next Steps With sentiment clearly split between risk and opportunity, it makes sense to review the details yourself and decide quickly where you stand, especially as our broader work highlights 3 key rewards and 1 important warning sign. Looking for more investment ideas? If Apellis has you rethinking your next move, do not stop here. Broaden your opportunity set now so you are not relying on a single story.  Target potential value opportunities early by scanning our list of 46 high quality undervalued stocks before they attract wider attention. Prioritise resilience with 77 resilient stocks with low risk scores so you are not caught off guard by companies with fragile fundamentals. Get ahead of the crowd by checking our screener containing 24 high quality undiscovered gems and spotting quality names before they become widely followed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614129518","isCrawlerRequest":true}